http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112017003898-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c539db959cc0106cab1662303f94fce
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65586
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-24
filingDate 2015-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86f98237f7f24b131aeac4eae377ee29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f149ef925273864851258a9e34f594a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcaa1d528bfc0f87f635076d15037e1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc843343d96d9ad5a6a7560977f7b36b
publicationDate 2022-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-112017003898-B1
titleOfInvention URIDINE DIOXOLAN ANALOG COMPOUND, PHARMACEUTICAL COMBINATION COMPRISING SUCH COMPOUND AND USE THEREOF FOR THE TREATMENT OF CANCER
abstract DIOXOLAN ANALOGS OF URIDINE FOR THE TREATMENT OF CANCER. The invention provides compounds of formula (I), wherein: R1 is OR11 or NR5R5'; R2 is H or F; R5 is H, C1-C6 alkyl, OH, C(=O)R6, O(C=O)R6 or O(C=O)OR6; R5? is H or C1-C6 alkyl; R6 is C1-C6 alkyl or C3-C7 cycloalkyl; R13 is H, phenyl, pyridyl, benzyl, indolyl or naphthyl, wherein the phenyl, pyridyl, benzyl, indolyl and naphthyl is optionally substituted with 1, 2 or 3 R22; and the other variables are as defined in the claims, which are for use in the treatment of cancer and related aspects.
priorityDate 2014-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523131
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7059438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547276
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426132196
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394834
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12586
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6029
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811

Total number of triples: 34.